AbbVie has acquired UK-based DJS Antibodies for $255 million.
DJS Antibodies Ltd. is a biotechnology company dedicated to discovering and developing antibody medicines that target disease-causing proteins, such as G protein-coupled receptors. DJS’ lead program is DJS-002, a potential first-in-class lysophosphatidic acid receptor 1 antagonist antibody currently in investigational preclinical studies for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. DJS is backed by founding investors Oxford Science Enterprises and Johnson & Johnson Innovation Ltd., along with LifeArc, Sedgwick Yard and Amgen Ventures.
AbbVie Inc. is a biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical products worldwide. The company focuses on several therapeutic areas, including immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.
According to the LevinPro HC database, this was the 115th Biotechnology deal of 2022. This compares with 100 Biotechnology transactions from January 1, 2021, to October 21, 2021.
